Taken together, these results provide evidence for FASN activity as a biological determinant that enables HRG-driven hormone-independence and refractoriness to SERMs (tamoxifen) and SERDs (fulvestrant) in ER+ breast cancer cells (Figure 4C). This evidence concerns the gene ESR1 and breast carcinoma.